R
Rarity Bioscience
Application: Rarity Safelock assay detects AML mutations
About Rarity Bioscience
Rarity Biosciences is a biotechnology startup that operates in the field of cancer diagnostics. The company's primary product is the superRCA, a highly sensitive and specific molecular amplification technology. This technology is designed to detect rare nucleic acid sequences, such as cancer mutations, in biological samples like liquid biopsies. In simpler terms, it can find very small amounts of DNA changes that could indicate cancer in a patient's tissue or blood samples.
Read full description
The superRCA technology is flexible and can be used in both research and clinical applications. It can detect multiple targets at once, a process known as multiplexing, making it a powerful tool for diagnosing cancer. The technology can be used in most hematology laboratories with existing equipment, making it more accessible and reducing response times for test results.
Rarity Biosciences serves a wide range of clients, including research institutions and clinical laboratories. The company's business model revolves around providing superRCA assays for research and service testing. Essentially, they make money by selling their technology and services to these institutions and laboratories.
The company was founded in 2021 as a spin-off from Uppsala University, with the aim of further developing and commercializing the superRCA technology. The technology was initially discovered and developed by PhD Lei Chen and Professor Ulf Landegren at the university's Department of Immunology, Genetics, and Pathology.
At a glance
- Founded
- 2021
- Headquarters
- Uppsala kommun, Sweden
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Rarity Bioscience.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Navigare Ventures
Novalis Biotech
Series A2 investors entered at this stage
Uppsala University Invest
Ulf Landegren
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rarity Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rarity Bioscience on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.